Royalty Pharma (RPRX) EPS (Basic) (2020 - 2026)

Royalty Pharma has disclosed EPS (Basic) across 7 years of filings, most recently posting $0.67 for Q1 2026.

• EPS (Basic) for Q1 2026 came in at $0.67, up 21.82% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.91 (down 22.67% YoY), and the FY2025 annual result was $1.79, down 6.77% from the prior year.
• EPS (Basic) came in at $0.67 for Q1 2026 at Royalty Pharma, up from $0.5 in the prior quarter.
• In the past five years, EPS (Basic) ranged from a high of $1.22 in Q3 2024 to a low of -$1.04 in Q4 2022.
• The 5-year median for EPS (Basic) is $0.5 (2025), against an average of $0.41.
• Across the five-year window, EPS (Basic) slumped 903.76% in 2022 and surged 5400.0% in 2025, its largest moves.
• Royalty Pharma's EPS (Basic) stood at -$1.04 in 2022, then surged by 206.73% to $1.11 in 2023, then tumbled by 57.66% to $0.47 in 2024, then grew by 6.38% to $0.5 in 2025, then surged by 34.0% to $0.67 in 2026.
• The last three EPS (Basic) figures came in at $0.67 (Q1 2026), $0.5 (Q4 2025), and $0.67 (Q3 2025), per Business Quant data.